Status:
COMPLETED
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
Lead Sponsor:
Pfizer
Conditions:
Osteoporosis
Eligibility:
FEMALE
55-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether bazedoxifene acetate is safe and effective in the treatment of osteoporosis in postmenopausal women.
Eligibility Criteria
Inclusion
- Must be at least 2 years postmenopausal
- Osteoporotic subjects without vertebral fracture who meet BMD criteria, or Osteoporotic subjects with vertebral fracture
Exclusion
- Diseases that may affect bone metabolism
- Vasomotor symptoms requiring treatment
- Known history or suspected cancer of the breast
- Active or past history of venous thromboembolic events
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
7609 Patients enrolled
Trial Details
Trial ID
NCT00205777
Start Date
December 1 2001
End Date
September 1 2010
Last Update
April 10 2013
Active Locations (375)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35249-7201
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294-3708
4
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801